H
Helena Escuin-Ordinas
Researcher at University of California, Los Angeles
Publications - 26
Citations - 5420
Helena Escuin-Ordinas is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 14, co-authored 20 publications receiving 3923 citations.
Papers
More filters
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso,Marios Giannakis,Marios Giannakis,Daniel K. Wells,Tsuyoshi Hamada,Xinmeng Jasmine Mu,Xinmeng Jasmine Mu,Michael J. Quist,Michael J. Quist,Jonathan A. Nowak,Reiko Nishihara,Zhi Rong Qian,Kentaro Inamura,Teppei Morikawa,Katsuhiko Nosho,Gabriel Abril-Rodriguez,Charles M. Connolly,Helena Escuin-Ordinas,Milan S. Geybels,William M. Grady,William M. Grady,Li Hsu,Siwen Hu-Lieskovan,Jeroen R. Huyghe,Yeon Joo Kim,Paige Krystofinski,Mark D.M. Leiserson,Dennis Montoya,Brian B. Nadel,Matteo Pellegrini,Colin C. Pritchard,Cristina Puig-Saus,Elleanor H. Quist,Benjamin J. Raphael,Stephen J. Salipante,Daniel Sanghoon Shin,Eve Shinbrot,Brian H. Shirts,Sachet A. Shukla,Sachet A. Shukla,Sachet A. Shukla,Janet L. Stanford,Janet L. Stanford,Wei Sun,Jennifer Tsoi,Alexander Upfill-Brown,David A. Wheeler,Catherine J. Wu,Catherine J. Wu,Ming Yu,Syed H.E. Zaidi,Jesse M. Zaretsky,Stacey Gabriel,Eric S. Lander,Levi A. Garraway,Levi A. Garraway,Thomas J. Hudson,Thomas J. Hudson,Charles S. Fuchs,Antoni Ribas,Shuji Ogino,Ulrike Peters,Ulrike Peters +62 more
TL;DR: This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that coloreCTal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion.
Journal ArticleDOI
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Richard Tavaré,Helena Escuin-Ordinas,Stephen Mok,Melissa N. McCracken,Kirstin A. Zettlitz,Felix B. Salazar,Owen N. Witte,Antoni Ribas,Anna M. Wu +8 more
TL;DR: The generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody for noninvasive immuno-PET tracking of endogenous CD8(+) T cells provides new opportunities to evaluate antitumor immune responses of immunotherapies currently being evaluated in the clinic.